Contact us Find us Register
Back to previous section

Berenberg cuts Hikma price target after update, maintains ‘buy’.

Berenberg cut its price target on Hikma Pharmaceuticals on Friday to 2,300p from 2,510p following the company’s trading update a day earlier, in which it downgraded medium-term guidance for the injectables unit.

  • Hikma Pharmaceuticals
  • 07 November 2025 09:50:09
Hikma Pharmaceuticals

Source: Sharecast

It noted that Hikma maintained its FY25 segmental guidance, but lowered its medium-term core operating profit growth guidance.

Hikma also now expects to be at the lower end of its previously-guided range for three-year group revenue compound annual growth rate, Berenberg said.

"We understand that these changes in medium-term profitability guidance are mainly attributable to a shift in timings for the ramp-up of its manufacturing site in Bedford (due to delays in the supply of machinery), with the site now expected to be operational towards the end of 2027E and with commercial production anticipated from 2028E.

"While disappointing, we think that many of the key drivers for the business remain intact (albeit they have been pushed slightly further out).

"Therefore, we factor the lower end of the medium-term guidance into our forecasts, update our price target and retain our ‘buy’ rating."

FTSE 100 ( UKX )

ISIN: N/A
Exchange: London Stock Exchange
Sell:
0.00
Buy:
0.00
Change: 4.43 ( 0.05 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.